The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
MERCK

Welcome

HIV INTERNET RESOURCES
Your gateway to some of the best resources on the Web...
Enter - HIV Internet Resources
ONLINE GLOSSARY
Taber’s Online (Cyclopedic Medical Dictionary)
THE HISTORY OF CRIXIVAN
When Merck launched its AIDS research program in January 1987, the pressure was already mounting from all sides. A protease inhibitor was not going to be an easy drug to develop—that much was known...
Enter - History of CRIXIVAN

CRIXIVAN® (indinavir sulfate) in combination with other antiretroviral agents is indicated for the treatment of HIV infection. This indication is based on 2 clinical trials of approximately 1 year’s duration that demonstrated (1) a reduction in the risk of AIDS-defining illness or death and (2) a prolonged suppression of HIV RNA.

CRIXIVAN:

  • Does not cure HIV infection
  • Does not reduce the transmission of HIV
  • Should only be taken in combination with other drugs for HIV

CRIXIVAN is contraindicated in patients with clinically significant hypersensitivity to any of its components.

For general information and other services for physicians
MERCK MEDICUSMERCK SOURCEMERCKServices
This site is intended only for healthcare professionals of the United States, its territories, and Puerto Rico.

CRIXIVAN is a registered trademark of Merck & Co., Inc.
20551267(2)-10/05-CRX